In contrast, miR‐221 and miR‐222 are up‐regulated in glioma cancer tissues and glioma cell lines to promote angiogenesis by targeting tissue inhibitor of metalloproteinase 2 (TIMP2), which inhibits the activity of matrix metalloproteinases (MMPs), thereby protecting the extracellular matrix from proteolytic degradation.67 Thus, the inhibition of miR‐221 and miR‐222 might be a potential prognostic and therapeutic tool in glioma cancer in future. This evidence concerns the gene TIMP2 and glioma.